Mankind Pharma Surges 8% Toward ₹2,500 on 27% EBITDA Margin and ₹740-Cr Debt Cut
Shares of domestic pharmaceutical leader Mankind Pharma witnessed strong buying interest on Tuesday, October 27, 2026, advancing as much as 8% during intraday trade to approach the key ₹2,500 threshold. The stock commenced the session on a positive note at ₹2,358.50 on Dalal Street, comfortably higher than its previous closing level of ₹2,312, before aggressive buying expanded its valuation, taking the company's total market capitalization to approximately ₹1,03,063 crore. While the single-session rally provided a sharp upside breakout from a period of range-bound trade—wherein the counter gained roughly 3% over the past year—the stock continues to consolidate below its historical record high of ₹3,054.80, remaining well clear of its cyclical low of ₹1,242 as investors assess whether the earnings beat marks the resumption of a long-term structural uptrend.
Strong 2QFY27 Operations: 27% Margin Outperformance, BSV Boost, and ₹740-Crore Deleveraging
The primary catalyst sparking Tuesday's rally was the company’s robust second-quarter performance for fiscal 2027 (2QFY27), characterized by broad-based volume growth across domestic finished formulations, integration synergies from Bharat Serums and Vaccines (BSV), and expanding traction in overseas markets. Operating revenue for the quarter surprised positively, outpacing JPMorgan’s baseline estimates by approximately 3%, while operational efficiency improved significantly as consolidated EBITDA margin came in at 27%—a notable 100-basis-point beat over street forecasts. Simultaneously, the pharmaceutical giant demonstrated balance-sheet discipline by significantly deleveraging its debt profile, slashing net debt from ₹33.8 billion (₹3,380 crore) in the June quarter to ₹26.4 billion (₹2,640 crore) by the end of September. This reduction of ₹7.4 billion (₹740 crore) materially lowers the group's ongoing interest burden and enhances financial flexibility. Even though second-quarter margins expanded to 27%, management prudently reiterated its full-year FY2027 EBITDA margin guidance within the 25.5% to 26.5% corridor, signaling a measured operational posture that accounts for second-half marketing investments and upcoming R&D commitments.
Divergent Street Views: Kotak Sets Street-High ₹3,035 Target, JPMorgan at ₹2,700, and Macquarie Retains ₹2,200
The robust quarterly report card triggered varied reactions among premier institutional brokerages, reflecting contrasting assessments of Mankind Pharma's medium-term earnings trajectory and fair valuation multiples. Taking the most optimistic stance, Kotak Institutional Equities assigned a street-high target price of ₹3,035 per share, projecting the company to outpace the broader domestic formulation market over the coming quarters and modeling a strong 23% compound annual growth rate (CAGR) in earnings per share (EPS) spanning the FY2026 to FY2029 period. Global investment bank JPMorgan maintained a balanced perspective with a price target of ₹2,700, acknowledging the operational beat in formulations, healthy export margins, and core base-business resilience, while keeping a watchful eye on consumer healthcare recovery and long-term volume sustainability. In contrast, Macquarie adopted a more cautious stance by setting its target price at ₹2,200, highlighting the valuation divergence across the street as market participants weigh single-day earnings enthusiasm against overall sector headwinds, promotional costs, and global pharmaceutical supply-chain dynamics.
